 |
 |
 |
 |
 |
 |
 |
 |
 |
The University of Michigan Scleroderma Program was organized in 2004 concomitant with the arrival of its director, James R.
Seibold,M.D., Marvin & Betty Danto Research Professor and Professor of Internal Medicine at the University of Michigan
Medical School. Scleroderma is an inherently complex disease which is best addressed by a multidisciplinary team
approach to treatment and research. The University of Michigan Medical School is one of the leading research institutions in
the world. Its clinical and scientific assets are extensive, cutting edge and uniquely suited to the needs of the scleroderma
community. The goals of the Scleroderma Program are to develop effective therapies for scleroderma and its complications
and to research the causes and mechanisms of disease. It is only through enhanced understanding of disease process
that cure will be possible. Based in the Division of Rheumatology, faculty from many disciplines, including Pulmonary
Medicine, the Pulmonary Hypertension Program of the Division of Cardiology, Pediatric Rheumatology, the Department of
Dermatology, the Division of Hand Surgery, the Department of Occupational Therapy; and the University of Michigan Cancer
Center, currently participate in Program activities. The Scleroderma Program provides clinical care, primarily on a
consultative basis to patients from Michigan and the Midwest, but also serves as an international referral center. Program
activities include development and performance of complex trials designed to improve the quality of life and extend survival.
Crucial to this enterprise is refined investigation of the science of outcome measures, which in turn, leads to more robustly
designed clinical trials for the future. An effective and talented team has been assembled and a broad portfolio of research
is in progress. Increasing focus is on initiatives in research into the cause and pathobiology of scleroderma. Basic
scientists are active at the University of Michigan in areas of direct relevance to scleroderma including the biology of fibrosis,
vascular biology, and basic cellular immunology.
The Scleroderma Program at the University of Michigan is dedicated to advancing research and improving care for patients
with scleroderma and related diseases.
University of Michigan Scleroderma ProgramFor more information, or to make a donation, please call 734-763-3110 or
visit our website:
Seibold,M.D., Marvin & Betty Danto Research Professor and Professor of Internal Medicine at the University of Michigan
Medical School. Scleroderma is an inherently complex disease which is best addressed by a multidisciplinary team
approach to treatment and research. The University of Michigan Medical School is one of the leading research institutions in
the world. Its clinical and scientific assets are extensive, cutting edge and uniquely suited to the needs of the scleroderma
community. The goals of the Scleroderma Program are to develop effective therapies for scleroderma and its complications
and to research the causes and mechanisms of disease. It is only through enhanced understanding of disease process
that cure will be possible. Based in the Division of Rheumatology, faculty from many disciplines, including Pulmonary
Medicine, the Pulmonary Hypertension Program of the Division of Cardiology, Pediatric Rheumatology, the Department of
Dermatology, the Division of Hand Surgery, the Department of Occupational Therapy; and the University of Michigan Cancer
Center, currently participate in Program activities. The Scleroderma Program provides clinical care, primarily on a
consultative basis to patients from Michigan and the Midwest, but also serves as an international referral center. Program
activities include development and performance of complex trials designed to improve the quality of life and extend survival.
Crucial to this enterprise is refined investigation of the science of outcome measures, which in turn, leads to more robustly
designed clinical trials for the future. An effective and talented team has been assembled and a broad portfolio of research
is in progress. Increasing focus is on initiatives in research into the cause and pathobiology of scleroderma. Basic
scientists are active at the University of Michigan in areas of direct relevance to scleroderma including the biology of fibrosis,
vascular biology, and basic cellular immunology.
The Scleroderma Program at the University of Michigan is dedicated to advancing research and improving care for patients
with scleroderma and related diseases.
University of Michigan Scleroderma ProgramFor more information, or to make a donation, please call 734-763-3110 or
visit our website:
